Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

BCLAF1 Regulates Expression of AP-1 Genes and Fetal Hematopoietic Stem Cell Repopulation Activity

Stephanie J. Crowley, Jeffrey J. Bednarski, Jeffrey A. Magee, Yanan LI, Lynn S. White, Wei Yang

Blood (2022) 140 (Supplement 1): 2852–2853.

https://doi.org/10.1182/blood-2022-162867

Published: 2022

Journal Articles

Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy

Madhav V. Dhodapkar, Rachael Sexton, Rituparna Das, Kavita M. Dhodapkar, Lin Zhang, Ranjini Sundaram, Sonal Soni, John J. Crowley, Robert Z. Orlowski, Bart Barlogie

Blood (2015) 126 (22): 2475–2478.

https://doi.org/10.1182/blood-2015-03-632919

Published: 2015

Includes: Supplemental data

Journal Articles

The Jak2 V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes

Gerlinde Wernig, Jeffrey R. Gonneville, Brian J. Crowley, Margret S. Rodrigues, Mamatha M. Reddy, Heidi E. Hudon, Christoph Walz, Andreas Reiter, Klaus Podar, Yohan Royer, Stefan N. Constantinescu, Michael H. Tomasson, James D. Griffin, D. Gary Gilliland, Martin Sattler

Blood (2008) 111 (7): 3751–3759.

https://doi.org/10.1182/blood-2007-07-102186

Published: 2008

Journal Articles

The Jak2 V617F Oncogene Associated with Polycythemia Vera Requires a Functional FERM Domain for Transformation and for Expression of the Myc and Pim Proto-Oncogenes.

Martin Sattler, PhD, Brian J. Crowley, Jeffrey R. Gonneville, Jeremy Ho, Heidi H. Hudon, Klaus Podar, M.D., Ph.D., Yohan Royer, Stefan N. Constantinescu, M.D., Ph.D., James D. Griffin, M.D.

Blood (2006) 108 (11): 3611.

https://doi.org/10.1182/blood.V108.11.3611.3611

Published: 2006

Journal Articles

A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples

Martin Sattler, Christoph Walz, Brian J. Crowley, Eva Lengfelder, Pasi A. Jänne, Andrew M. Rogers, Yanan Kuang, Robert J. Distel, Andreas Reiter, James D. Griffin

Blood (2006) 107 (3): 1237–1238.

https://doi.org/10.1182/blood-2005-07-2899

Published: 2006

Journal Articles

Multiple Myeloma (MM) in Young Patients (pts): Clinical Features and Outcome in 259 Patients Younger Than 40 Years in Comparison to 8,296 pts Aged ≥ 40 Years.

Blood (2005) 106 (11): 3414.

https://doi.org/10.1182/blood.V106.11.3414.3414

Published: 2005

Journal Articles

The Jak2V617F Oncogene Associated with Polycythemia Vera Regulates G1/S-Phase Transition.

Martin Sattler, PhD, Christoph Walz, Brian J. Crowley, BS, Jessica L. Gramlich, BS, Kendra L. King, Klaus Podar, MD, James D. Griffin, MD

Blood (2005) 106 (11): 3510.

https://doi.org/10.1182/blood.V106.11.3510.3510

Published: 2005

Journal Articles

A Novel Heterologous Expression System for Characterization of Individual NADH-Cytochrome b 5 Reductase Variants in Recessive Congenital Methemoglobinemia.

Melanie J. Percy, PhD, L. J. Crowley, PhD, C. A. Davis, PhD, J. Boudreaux, MD, D. M. Layton, MD, M. F. McMullin, MD, T. R. Lappin, PhD, M. J. Barber, DPhil

Blood (2005) 106 (11): 1676.

https://doi.org/10.1182/blood.V106.11.1676.1676

Published: 2005

Journal Articles

Bortezomib Therapy Alone and in Combination with Dexamethasone for Patients with Previously Untreated Multiple Myeloma.

Sundar Jagannath, B. Durie, J. Wolf, E. Camacho, D. Irwin, J. Lutzky, M. McKinley, E. Gabayan, A. Mazumder, J. Crowley, R. Vescio, D. Schenkein

Blood (2005) 106 (11): 783.

https://doi.org/10.1182/blood.V106.11.783.783

Published: 2005

Journal Articles

SWOG 0204; Phase 2 Trial of Thalidomide (T) + Dexamethasone (D) Induction Followed by Tandem Autotransplant (TAT) and Prednisone (P) + T Maintenance for Multiple Myeloma (MM).

Mohamad A. Hussein, MD, Jason McCoy, MS, Andrzej Jakubowiak, MD, PhD, Brian G. Durie, MD, John J. Crowley, MD, Bart Barlogie, MD, PhD

Blood (2005) 106 (11): 1169.

https://doi.org/10.1182/blood.V106.11.1169.1169

Published: 2005

Journal Articles

Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628

Madhav V. Dhodapkar, Mohamad A. Hussein, Erik Rasmussen, Alan Solomon, Richard A. Larson, John J. Crowley, Bart Barlogie

Blood (2004) 104 (12): 3520–3526.

https://doi.org/10.1182/blood-2004-05-1924

Published: 2004

Journal Articles

Extreme Regression: A Statistical Technique for Finding Good or Poor Prognostic Groups, Illustrated Using Myeloma Patient Data from Intergroup Trial S9321.

John J. Crowley, PhD, Jason McCoy, MS, Michael LeBlanc, PhD, Bart Barlogie, MD, PhD

Blood (2004) 104 (11): 5202.

https://doi.org/10.1182/blood.V104.11.5202.5202

Published: 2004

Journal Articles

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients

James R. Berenson, John J. Crowley, Thomas M. Grogan, Jeffrey Zangmeister, Adrienne D. Briggs, Glenn M. Mills, Bart Barlogie, Sydney E. Salmon

Blood (2002) 99 (9): 3163–3168.

https://doi.org/10.1182/blood.V99.9.3163

Published: 2002

Journal Articles

Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003)

Madhav V. Dhodapkar, Joth L. Jacobson, Morie A. Gertz, Saul E. Rivkin, G. David Roodman, Joseph M. Tuscano, Muhammad Shurafa, Robert A. Kyle, John J. Crowley, Bart Barlogie

Blood (2001) 98 (1): 41–48.

https://doi.org/10.1182/blood.V98.1.41

Published: 2001

Journal Articles

Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma

Blood (1999) 93 (1): 55–65.

https://doi.org/10.1182/blood.V93.1.55

Published: 1999

Journal Articles

Autotransplants in multiple myeloma: what have we learned?

DH Vesole, G Tricot, S Jagannath, KR Desikan, D Siegel, D Bracy, L Miller, B Cheson, J Crowley, B Barlogie

Blood (1996) 88 (3): 838–847.

https://doi.org/10.1182/blood.V88.3.838.838

Published: 1996

Journal Articles

Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients

G Tricot, S Jagannath, D Vesole, J Nelson, S Tindle, L Miller, B Cheson, J Crowley, B Barlogie

Blood (1995) 85 (2): 588–596.

https://doi.org/10.1182/blood.V85.2.588.588

Published: 1995

Journal Articles

High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants

DH Vesole, B Barlogie, S Jagannath, B Cheson, G Tricot, R Alexanian, J Crowley

Blood (1994) 84 (3): 950–956.

https://doi.org/10.1182/blood.V84.3.950.950

Published: 1994

Journal Articles

Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support

S Jagannath, DH Vesole, L Glenn, J Crowley, B Barlogie

Blood (1992) 80 (7): 1666–1672.

https://doi.org/10.1182/blood.V80.7.1666.1666

Published: 1992

Journal Articles

Prognostic correlation of plasma cell acid phosphatase and beta- glucuronidase in multiple myeloma: a Southwest Oncology Group study [see comments]

SM Saeed, D Stock-Novack, R Pohlod, J Crowley, SE Salmon

Blood (1991) 78 (12): 3281–3287.

https://doi.org/10.1182/blood.V78.12.3281.3281

Published: 1991

NARROW

BCLAF1 Regulates Expression of AP-1 Genes and Fetal Hematopoietic Stem Cell Repopulation Activity

Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy

The Jak2 V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes

The Jak2 V617F Oncogene Associated with Polycythemia Vera Requires a Functional FERM Domain for Transformation and for Expression of the Myc and Pim Proto-Oncogenes.

A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples

Multiple Myeloma (MM) in Young Patients (pts): Clinical Features and Outcome in 259 Patients Younger Than 40 Years in Comparison to 8,296 pts Aged ≥ 40 Years.

The Jak2V617F Oncogene Associated with Polycythemia Vera Regulates G1/S-Phase Transition.

A Novel Heterologous Expression System for Characterization of Individual NADH-Cytochrome b 5 Reductase Variants in Recessive Congenital Methemoglobinemia.

Bortezomib Therapy Alone and in Combination with Dexamethasone for Patients with Previously Untreated Multiple Myeloma.

SWOG 0204; Phase 2 Trial of Thalidomide (T) + Dexamethasone (D) Induction Followed by Tandem Autotransplant (TAT) and Prednisone (P) + T Maintenance for Multiple Myeloma (MM).

Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628

Extreme Regression: A Statistical Technique for Finding Good or Poor Prognostic Groups, Illustrated Using Myeloma Patient Data from Intergroup Trial S9321.

Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients

Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003)

Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma

Autotransplants in multiple myeloma: what have we learned?

Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients

High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants

Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support

Prognostic correlation of plasma cell acid phosphatase and beta- glucuronidase in multiple myeloma: a Southwest Oncology Group study [see comments]

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only